Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer

BACKGROUND: We previously reported that the addition of erlotinib to gemcitabine and oxaliplatin (GEMOX) resulted in greater antitumor activity and might be a treatment option for patients with biliary tract cancers (BTCs). Molecular subgroup analysis of treatment outcomes in patients who had specim...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Seung Tae Kim, Kee-Taek Jang, Jeeyun Lee, Heung-Moon Jang, Hye-Jin Choi, Hye-Lim Jang, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Joon Oh Park
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2015-02-01
Saila:Translational Oncology
Sarrera elektronikoa:http://www.sciencedirect.com/science/article/pii/S1936523314001375
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak